The company’s revenue also witnessed a jump of 5% on a year-on-year basis to Rs 2,221 crore for the second quarter ended September 2024, while the same was up by 8% YoY for H1FY25.
EBITDA for the reporting quarter stood at Rs 628.9 crore, which was up by 14% YoY.
During the quarter, PI Industries completed the acquisition of global biologicals company Plant Health Care.
PI Industries also reduced its trade working capital from 84 to 70 days.
Also Read: Niva Bupa Healthcare shares list at 6% premium over IPO price10% growth in Agchem exports was reported, mainly driven by volume growth and growth of new products while the new products growth stood at 42% YoY. The domestic revenues were subdued with a reduction of 5% YoY due to a reduced supply to institutional customers.Biological products’ drove the company’s growth and the revenue increased by 18% YoY and the pharma contributed exports revenue of Rs 41.1 crore i.e, 2% of total exports revenue.
Gross Margin improved to 52%, an improvement of 519 bps year-on-year mainly on account of better product mix and operative leverage.
Also read: NALCO shares rally 5% after Q2 profit rises multi-fold to Rs 1,046 crore
The shares of PI Industries have increased by 14.41% in the last one year while gaining 20.9% in the current year so far. However, the same has witnessed a decline of 3% and 8% over the last 3 months and 1 month respectively.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)